you are here: HomeNewsCipla
cipla
Jump to
2251 Results Found
  • Buy Cipla; target of Rs 940: Dolat Capital Market Feb 09, 2021 11:48 PM IST

    Buy Cipla; target of Rs 940: Dolat Capital Market

    Dolat Capital Market is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 940 in its research report dated January 31, 2021.

  • Buy Cipla; target of Rs 950: Sharekhan Feb 08, 2021 04:07 PM IST

    Buy Cipla; target of Rs 950: Sharekhan

    Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 950 in its research report dated January 29, 2021.

  • Accumulate Cipla; target of Rs 913: Prabhudas Lilladher Feb 04, 2021 06:51 PM IST

    Accumulate Cipla; target of Rs 913: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Cipla with a target price of Rs 913 in its research report dated February 01, 2021.

  • Buy Cipla; target of Rs 975: ICICI Direct Feb 04, 2021 05:23 PM IST

    Buy Cipla; target of Rs 975: ICICI Direct

    ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 975 in its research report dated January 30, 2021.

  • Lupin: New launches and market share gains are likely to override pricing erosion Feb 03, 2021 09:57 AM IST

    Lupin: New launches and market share gains are likely to override pricing erosion

    New launches in the US, particularly in the inhalation category, and an improving market share are expected to help ride over structural pricing erosion in the near term for Lupin

  • Neutral Cipla; target of Rs 900: Motilal Oswal Feb 02, 2021 09:07 PM IST

    Neutral Cipla; target of Rs 900: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 900 in its research report dated January 30, 2021.

  • Buy Cipla; target of Rs 1020: HDFC Securities Feb 02, 2021 02:33 PM IST

    Buy Cipla; target of Rs 1020: HDFC Securities

    HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1020 in its research report dated February 01, 2021.

  • Cipla Consolidated December 2020 Net Sales at Rs 5,168.69 crore, up 18.25% Y-o-Y Feb 02, 2021 09:44 AM IST

    Cipla Consolidated December 2020 Net Sales at Rs 5,168.69 crore, up 18.25% Y-o-Y

  • Cipla Standalone December 2020 Net Sales at Rs 3,731.55 crore, up 27.52% Y-o-Y Feb 02, 2021 09:11 AM IST

    Cipla Standalone December 2020 Net Sales at Rs 3,731.55 crore, up 27.52% Y-o-Y

  • Pharma: Ignore the noise as the core allocation is incremental Feb 01, 2021 07:32 PM IST

    Pharma: Ignore the noise as the core allocation is incremental

    Focus on creating health infrastructure in the Budget 2021 is clearly an incrementally structural move which should indirectly benefit all the domestic oriented companies

  • Cipla — Large part of COVID opportunity has played out Jan 31, 2021 12:48 PM IST

    Cipla — Large part of COVID opportunity has played out

    In the US market, Albuterol opportunity remains a key lever for Cipla at least till the time Perrigo re-enters although in terms of market share, the drugmaker may be close to maturity

  • Cipla posts strong Q3 numbers, profit more than doubles to Rs 748.15 crore Jan 29, 2021 05:07 PM IST

    Cipla posts strong Q3 numbers, profit more than doubles to Rs 748.15 crore

    The company's revenue for the quarter came at Rs 5,168.7 crore, up 18.2 percent from Rs 4,371 crore in the year-ago quarter.

  • Cipla Q3 PAT seen up 74.3% YoY to Rs. 612 cr: Yash Securities Jan 22, 2021 12:59 PM IST

    Cipla Q3 PAT seen up 74.3% YoY to Rs. 612 cr: Yash Securities

    Net Sales are expected to increase by 14 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 4985 crore, according to Yash Securities.

  • Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher Jan 18, 2021 10:57 PM IST

    Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 15.3 percent Y-o-Y (down 1.8 percent Q-o-Q) to Rs. 4,234.6 crore, according to Prabhudas Lilladher.

  • Cipla Q3 PAT seen up 73.2% YoY to Rs. 608.1 cr: ICICI Direct Jan 18, 2021 08:08 PM IST

    Cipla Q3 PAT seen up 73.2% YoY to Rs. 608.1 cr: ICICI Direct

    Net Sales are expected to increase by 15.7 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 5,057.6 crore, according to ICICI Direct.

  • Will normalcy return to COVID-hit Indian pharmaceutical market in 2021? Dec 31, 2020 02:15 PM IST

    Will normalcy return to COVID-hit Indian pharmaceutical market in 2021?

    The pharmaceutical sector is expecting sales to normalise by the second half of 2021, with the availability of COVID-19 vaccine and coronavirus receding.

  • Quant Pick - Cipla: ICICI Direct Dec 22, 2020 12:58 PM IST

    Quant Pick - Cipla: ICICI Direct

    According to ICICI Direct, Buy Cipla in range of Rs 790-807 Target: Rs 930 Stop Loss: Rs 725 Time frame: Three months.

  • Cipla share price gains on launching rapid antigen detection test Dec 16, 2020 09:36 AM IST

    Cipla share price gains on launching rapid antigen detection test

    The company will commence the supply of rapid antigen test kits for COVID-19 in India from this week.

  • Buy Cipla; target of Rs 940: HDFC Securities Dec 14, 2020 01:39 PM IST

    Buy Cipla; target of Rs 940: HDFC Securities

    HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 940 in its research report dated December 14, 2020.

  • Buy Cipla; target of Rs 887: Prabhudas Lilladher Dec 14, 2020 01:37 PM IST

    Buy Cipla; target of Rs 887: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 887 in its research report dated December 14, 2020.

  • Cipla share price jumps 5% after settlement with Celgene Corp Dec 14, 2020 09:39 AM IST

    Cipla share price jumps 5% after settlement with Celgene Corp

    Nomura has maintained buy rating with a target at Rs 861 per share.

  • Hold Cipla; target of Rs 836: Prabhudas Lilladher Nov 12, 2020 04:01 PM IST

    Hold Cipla; target of Rs 836: Prabhudas Lilladher

    Prabhudas Lilladher recommended Hold rating on Cipla with a target price of Rs 836 in its research report dated November 09, 2020.

  • Buy Cipla: target of Rs 950: Sharekhan Nov 11, 2020 11:29 AM IST

    Buy Cipla: target of Rs 950: Sharekhan

    Sharekhan is bullish on Cipla recommended buy rating on the stock with a target price of Rs 950 in its research report dated November 06, 2020.

  • Indian demand for COVID-19 drug Remdesivir rising sharply: Cipla Nov 09, 2020 02:51 PM IST

    Indian demand for COVID-19 drug Remdesivir rising sharply: Cipla

    Remdesivir was developed by US drugmaker Gilead Sciences Inc , which cut its 2020 revenue forecast last month, citing lower-than-expected demand and difficulty in predicting sales of the treatment. Cipla is among several firms licensed to make and sell generic versions in developing nations.

  • Buy Cipla; target of Rs 942: Dolat Capital Market Nov 09, 2020 01:38 PM IST

    Buy Cipla; target of Rs 942: Dolat Capital Market

    Dolat Capital Market is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 942 in its research report dated November 07, 2020.

Sections